Indication

In adults and adolescents 12 years and older as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fractional exhaled nitric oxide (FeNO), who are inadequately controlled with high dose inhaled corticosteroid (ICS) plus another medicinal product for maintenance treatment.

Medicine details

Medicine name:
dupilumab (Dupixent)
SMC ID:
SMC2317
Pharmaceutical company
Sanofi
BNF chapter
Respiratory system
Submission type
Full
Publication due date:
12 April 2021
SMC meeting date:
02 March 2021
Patient group submission deadline:
01 February 2021